<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04681118</url>
  </required_header>
  <id_info>
    <org_study_id>BCT-003-US</org_study_id>
    <nct_id>NCT04681118</nct_id>
  </id_info>
  <brief_title>Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS</brief_title>
  <official_title>Intermediate-size Patient Population Expanded Access Protocol: Repeated Administration of Nurown® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brainstorm-Cell Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brainstorm-Cell Therapeutics</source>
  <brief_summary>
    <textblock>
      Expanded Access for treatment with investigational product MSC-NTF cells(NurOwn®) for&#xD;
      participants who completed all scheduled treatments and follow-up assessments in BCT-002-US&#xD;
      study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an Intermediate-size patient population Expanded Access Protocol (EAP) to provide&#xD;
      NurOwn® (MSC-NTF cells) for eligible ALS participants who completed the BCT-002-US phase 3&#xD;
      ALS clinical trial and have received all three IT treatments.&#xD;
&#xD;
      The participants will undergo up to three intrathecal (IT) treatments with NurOwn® (MSC-NTF&#xD;
      cells).&#xD;
&#xD;
      The first treatment will be at Visit 3, approximately 5-6 weeks after the BMA (Visit 2), with&#xD;
      the subsequent treatments at Visit 4 and Visit 5.&#xD;
&#xD;
      Following the third and last treatment, the participant will be followed for three additional&#xD;
      monthly visits (in-person, if feasible, or by telephone call or telemedicine in consideration&#xD;
      of the ongoing COVID-19 pandemic) through week 28, during which the ALSFRS-R and safety&#xD;
      assessments will be collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NurOwn (MSC-NTF cells)</intervention_name>
    <description>Intrathecal administration</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Participation in the BCT-002-US study, successful completion of all scheduled treatments&#xD;
        and follow-up assessments.&#xD;
&#xD;
        2 Able to provide to the Investigator written informed consent regarding the&#xD;
        investigational drug, or, as applicable, on whose behalf a legally authorized&#xD;
        representative of the participant has provided such consent.&#xD;
&#xD;
        3. Able to safely undergo a bone marrow aspiration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to lie flat for the duration of intrathecal cell transplantation and/or bone&#xD;
             marrow biopsy, or inability to tolerate treatment procedures for any other reason&#xD;
             (lying flat with BiPAP or NIV are not exclusionary).&#xD;
&#xD;
          2. History of clinically significant autoimmune disease (excluding thyroid disease)&#xD;
             myelodysplastic or myeloproliferative disorder, leukemia or lymphoma, whole body&#xD;
             irradiation, hip fracture, or severe scoliosis.&#xD;
&#xD;
          3. Any unstable clinically significant medical condition other than ALS (e.g., within six&#xD;
             months of baseline, had myocardial infarction, angina pectoris, and/or congestive&#xD;
             heart failure), treatment with anticoagulants that, in the opinion of the&#xD;
             Investigator, would compromise the safety of the participant.&#xD;
&#xD;
          4. Any history of malignancy within the previous 5 years, with the exception of non-&#xD;
             melanoma localized skin cancers (with no evidence of metastasis, significant invasion,&#xD;
             or re-occurrence within three years of baseline).&#xD;
&#xD;
          5. Current use of immunosuppressant medication or use of such medication within 4 weeks&#xD;
             of the pre-treatment visit.&#xD;
&#xD;
          6. Any history of acquired or inherited immune deficiency syndrome.&#xD;
&#xD;
          7. Tracheostomy and/or mechanical ventilation. Feeding tube use, BiPAP or NIV are not&#xD;
             exclusionary.&#xD;
&#xD;
          8. Pregnant women or women currently breastfeeding or unwilling to use effective birth&#xD;
             control methods during the treatment (if of childbearing age).&#xD;
&#xD;
          9. Positive test result for Hepatitis B virus (HBV; surface antigen (HBsAg) and IgM&#xD;
             antibodies to core antigen (IgM anti-HBc)), Hepatitis C virus (HCV), Human Immune&#xD;
             deficiency virus (HIV) 1 and 2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>63 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Mary Kay Turner</last_name>
    <phone>201-488-0460</phone>
    <phone_ext>105</phone_ext>
    <email>mkt@brainstorm-cell.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yael Gothelf, Ph.D.</last_name>
    <phone>646-666-3188</phone>
    <phone_ext>111</phone_ext>
    <email>ygothelf@brainstorm-cell.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California Irvine Alpha Stem Cell Clinic</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Namita A Goyal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Matthew H Burford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Jonathan Katz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>James D Berry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMass Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Robert H Brown, D.Phil., M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <investigator>
      <last_name>Anthony Windebank, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>December 18, 2020</last_update_submitted>
  <last_update_submitted_qc>December 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

